½ÃÀ庸°í¼­
»óǰÄÚµå
1766360

Áú ½½¸µ ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)

Vaginal Slings Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Áú ½½¸µ ½ÃÀåÀº 2024³â 18¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í 2034³â¿¡´Â 41¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 8.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀº ÁÖ·Î ¿ä½Ç±Ý »ç·ÊÀÇ Áõ°¡, ¿©¼ºµéÀÇ °ñ¹ÝÀú ±â´É¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í, ½½¸µ Àç·á ¹× ¼ö¼ú ¹æ¹ýÀÇ ¹ßÀü¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. °ø°ø ÀÎ½Ä Ä·ÆäÀÎ, ¿ËÈ£ Ȱµ¿, ±³À° ÇÁ·Î±×·¥ µîÀ» ÅëÇØ ¿©¼ºµéÀÌ ÀÌ¿ë °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇØ ´õ ¸¹ÀÌ ¾Ë°Ô µÇ¸é¼­, Á¶±â Áø´Ü°ú ¼ö¼ú ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Èí¼ö¼º ¹× °æ·® ¼ÒÀç¿Í °°Àº ½½¸µ µðÀÚÀÎÀÇ ±â¼úÀû Áøº¸´Â ¼ö¼ú °á°ú¿Í ȯÀÚ ¸¸Á·µµ¸¦ °³¼±Çß½À´Ï´Ù. ¿Ü·¡ ¼ö¼ú·Î ÀüȯµÇ´Â Ãß¼¼´Â ºñ¿ë È¿À²¼º, ªÀº ȸº¹ ½Ã°£, °íǰÁú Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ÀÇ·á ±â°ü Àü¹Ý¿¡¼­ ÀüüÀûÀΠäÅ÷üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÃÖ¼Ò Ä§½ÀÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Á¦Ç° °³¹ßÀ» °è¼ÓÇØ¼­ ÁÖµµÇϰí ÀÖÀ¸¸ç, ¾÷°è Àü¹Ý¿¡ °ÉÃÄ ¼ÒºñÀÚÀÇ ¼±Åÿ¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Áú ½½¸µ ½ÃÀå-IMG1

2024³â¿¡´Â °æ°ñ°ñ¹Ý ½½¸µ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇϸç 7¾ï 3,920¸¸ ´Þ·¯ÀÇ °¡Ä¡¸¦ ´Þ¼ºÇß½À´Ï´Ù. ÀÌ ¹æ¹ýÀº Áß¿äÇÑ Ç÷°ü ¹× ½Å°æ ºÎÀ§¸¦ ÇÇÇÏ¿© ÇÕº´ÁõÀ» ÁÙÀÓÀ¸·Î½á ´õ ¾ÈÀüÇÑ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ½½¸µÀº Ä¡°ñ ÈĺΠºÎÀ§¸¦ ¿ìȸÇÏ¿© È¿°úÀûÀÎ ÁöÁö·ÂÀ» Á¦°øÇϸ鼭 ¿Ü»óÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ÀÌ Á¦Ç°ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ´Â °ÍÀº ¾ÈÀü¼º Çâ»ó, »ðÀÔ ¿ëÀ̼º ¹× À¯¸®ÇÑ È¯ÀÚ °á°ú¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¸¹Àº Á¦Á¶¾÷üµéÀÌ ÀÌ·¯ÇÑ ¿ä±¸ »çÇ×À» ÃæÁ·Çϱâ À§ÇØ Á¦Ç° ¼³°è¸¦ °³¼±ÇÏ¿© ºÎ¹®ÀÇ ¼ºÀå°ú »ç¿ëÀÚ ½Å·Ú¸¦ ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 18¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 41¾ï ´Þ·¯
CAGR 8.2%

2024³â ±âÁØ ½ºÆ®·¹½º ¿ä½Ç±ÝÀÌ Áú ½½¸µ ½ÃÀå Á¡À¯À²ÀÇ 41.2%¸¦ Â÷ÁöÇß½À´Ï´Ù. ³ë·É Àα¸, ƯÈ÷ ¿©¼ºÀÇ Áõ°¡·Î °ñ¹ÝÀú ±ÙÀ° ¾àÈ­ À§ÇèÀÌ ³ô¾ÆÁö¸ç, ÀÌ´Â ½ºÆ®·¹½º ¿ä½Ç±ÝÀ¸·Î À̾îÁý´Ï´Ù. ¹Ì±¹ alone¿¡¼­ ¼ö¹é¸¸ ¸íÀÇ ¼ºÀÎ ¿©¼º¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ÀÌ ÁúȯÀº ½É°¢ÇÑ ÀÇ·á ºÎ´ãÀ» ÃÊ·¡ÇÕ´Ï´Ù. Áú ½½¸µÀº ³ë·É Àα¸¿¡¼­ ÀÌ·¯ÇÑ Áõ»óÀ» °ü¸®ÇÏ´Â ½Å·ÚÇÒ ¼ö ÀÖ°í È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇß½À´Ï´Ù. ¿©¼ºÀÇ ºñ´¢±â °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­, ƯÈ÷ ÅëÁõ¼º ¹æ±¤ ÁõÈıº°ú °°Àº Áúȯ¿¡ ´ëÇÑ °ü½ÉÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä½Ç±Ý °ü·Ã ¹®Á¦ ÇØ°áÀ» ¸ñÇ¥·Î ÇÑ °úÇÐÀû ¿¬±¸¿Í Á¦Ç° Çõ½ÅÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸ÂÃãÇü, ¾ÈÀüÇϰí È¿À²ÀûÀÎ Ä¡·á ¿É¼ÇÀÎ ÀڱðæºÎ ½½¸µ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Áú ½½¸µ ½ÃÀåÀº 2024³â¿¡ 3¾ï 9,680¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ÀÌ ½ÃÀåÀº ½ºÆ®·¹½º¼º ¿ä½Ç±Ý(SUI)À¸·Î °íÅë¹Þ´Â ¿©¼º, ƯÈ÷ °í·É Àα¸ÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ²ÙÁØÇÑ ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. °ñ¹Ý °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Àü¹® ºñ´¢±â°ú ¼¾ÅÍ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ´õ ¸¹Àº ¿©¼ºµéÀÌ ¿ä½Ç±Ý Ä¡·á¸¦ ¹Þ±â ½ÃÀÛÇß½À´Ï´Ù. ºñ¸¸, Ãâ»ê, Æó°æ°ú °°Àº ¿äÀεéÀÌ °ñ¹ÝÀú ±â´É Àå¾ÖÀÇ ¹ßº´·üÀ» °è¼Ó ³ôÀÓ¿¡ µû¶ó Áú ½½¸µ°ú °°Àº ¿Ü°úÀû °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½½¸µ Àç·áÀÇ ¹ßÀü°ú ÃÖ¼Ò Ä§½À ¼ö¼ú ±â¹ýÀÇ Ã¤ÅÃÀ¸·Î ½Ã¼ú È¿À²ÀÌ Çâ»óµÇ°í ȸº¹ ½Ã°£ÀÌ ´ÜÃàµÇ¸ç Àü¹ÝÀûÀΠȯÀÚ ¸¸Á·µµ°¡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀÌ ½ÃÀå È®ÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °­·ÂÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í À¯¸®ÇÑ º¸Çè ȯ±Þ Á¤Ã¥ÀÌ ¹Ì±¹ Àü¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Àü ¼¼°è Áú ½½¸µ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â UroCure, A.M.I., Betatech, Coloplast, UNISUR, Boston Scientific, ADLER, Promedon, CALDERA MEDICAL, Johnson & Johnson, COUSIN SURGERY, neomedic international, LOTUS ¹× B. BraunÀÌ ÀÖ½À´Ï´Ù. Áú ½½¸µ ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ÁÖ¿ä ¾÷üµéÀº Çõ½Å, Á¢±Ù¼º, Àü ¼¼°è ÁøÃâÀ» ¸ðµÎ ÁßÁ¡ÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ ºü¸¥ ȸº¹À» Áö¿øÇÏ°í ¼ö¼úÀÇ º¹À⼺À» ÁÙÀÌ´Â °æ·®, »ýü ÀûÇÕ¼º, ȯÀÚ Áß½ÉÀÇ ½½¸µ ¼ÒÀç·Î Á¦Ç° ¶óÀÎÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â°ü ¹× ¿Ü°úÀǵé°ú Àü·«Àû Çù·ÂÀ» ÅëÇØ ½Ã¼ú äÅà ¹× Á¦Ç° Çǵå¹éÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¾÷µéÀº Áö¸®Àû ¹üÀ§¸¦ È®´ëÇϱâ À§ÇØ ÀÓ»ó ½ÃÇè ¹× ±ÔÁ¦ ½ÂÀÎÀ» À§ÇÑ ÅõÀÚµµ ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ °íÂû

  • »ýÅÂ°è ºÐ¼®
    • °ø±ÞÀÚÀÇ »óȲ
    • °¢ ´Ü°è¿¡¼­ÀÇ ºÎ°¡°¡Ä¡
    • ¹ë·ùüÀο¡ ¿µÇâÀ» ÁÖ´Â ¿äÀÎ
  • »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¿ä½Ç±Ý(UI)ÀÇ ±Þ°ÝÇÑ Áõ°¡
      • ºÎÀΰú Áúȯ Áõ°¡
      • ¼ö¼ú ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü
      • °ñ¹ÝÀú Àå¾Ö ¹× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Çâ»ó
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ© ¹× °úÁ¦
      • Áú ½½¸µ ½Ã¼úÀÇ ³ôÀº ºñ¿ë
      • ¾ÈÀü¼º°ú À¯È¿¼º¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
    • ºÏ¹Ì
    • À¯·´
    • ±âŸ
  • ±â¼ú°ú Çõ½ÅÀÇ »óȲ
    • ÇöÀçÀÇ ±â¼ú µ¿Çâ
    • ½ÅÈï±â¼ú
  • °¡°Ý µ¿Çâ
    • Áö¿ªº°
    • Á¦Ç°º°
  • Àå·¡ ½ÃÀå µ¿Çâ
  • »óȯ ½Ã³ª¸®¿À
    • »óȯ ½ÃÃ¥ÀÌ ½ÃÀå ¼ºÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • ¼ÒºñÀÚ Çൿ ºÐ¼®
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
    • ¼¼°è
    • ºÏ¹Ì
    • À¯·´
    • ±âŸ
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
    • ÇÕº´°ú Àμö
    • ÆÄÆ®³Ê½Ê ¹× Çù¾÷
    • ½ÅÁ¦Ç° ¹ß¸Å
    • È®´ë °èȹ

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Á¦Ç°º°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • °æ°ñ°ñ¹Ý ½½¸µ
  • ¹«Àå·Â Áú Å×ÀÌÇÁ ½½¸µ
  • ¹Ì´Ï ½½¸µ

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ½Ç±Ý À¯Çüº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ½ºÆ®·¹½º¼º ¿ä½Ç±Ý
  • È¥ÇÕ¼º ½Ç±Ý
  • Àý¹Ú¼º ¿ä½Ç±Ý

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : À¯Çüº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • °æ´¢µµÀû ½½¸µ
  • ÀüÅëÀû ½½¸µ

Á¦8Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦9Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ADLER
  • AMI
  • B. Braun
  • Betatech
  • Boston Scientific
  • CALDERA MEDICAL
  • Coloplast
  • COUSIN SURGERY
  • Johnson& Johnson
  • LOTUS
  • neomedic international
  • Promedon
  • UNISUR
  • UroCure
HBR 25.07.16

The Global Vaginal Slings Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 8.2% to reach USD 4.1 billion by 2034. This notable expansion is primarily driven by a rise in urinary incontinence cases, increased awareness of pelvic floor conditions among women, and advancements in sling materials and surgical methods. An increasing number of women are becoming more informed about available treatments due to public awareness campaigns, advocacy initiatives, and educational programs. These efforts have encouraged earlier diagnosis and increased acceptance of surgical options. Additionally, technological progress in sling design, such as absorbable and lightweight materials, has improved procedural outcomes and patient satisfaction. The shift toward outpatient procedures, which offer cost-effectiveness, shorter recovery times, and high-quality care, is also boosting overall adoption across healthcare settings. Demand for minimally invasive and patient-friendly procedures continues to shape product development and influence consumer choices across the industry.

Vaginal Slings Market - IMG1

The transobturator slings segment led the market in 2024, reaching a valuation of USD 739.2 million. This method offers a safer alternative by avoiding critical vascular and nerve zones, thereby reducing complications. By bypassing the retropubic area, these slings minimize trauma while delivering effective support. Their increasing adoption is linked to improved safety, ease of placement, and favorable patient outcomes. Many manufacturers have refined their product designs to accommodate these requirements, contributing to higher segment growth and user trust.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.8 Billion
Forecast Value$4.1 Billion
CAGR8.2%

In 2024, stress incontinence held the largest share at 41.2% of the vaginal slings market. The growing elderly population, particularly women, faces higher risks of pelvic floor weakening, which often results in stress urinary incontinence. With millions of adult females affected in the U.S. alone, this condition presents a significant healthcare burden. Vaginal slings offer a reliable and effective treatment for managing these symptoms in aging demographics. Rising awareness surrounding women's urological health, particularly conditions like painful bladder syndrome, has further accelerated scientific research and product innovations targeting incontinence-related issues. As a result, the demand for tailored, safe, and efficient treatment options like vaginal slings continues to rise.

U.S. Vaginal Slings Market was valued at USD 396.8 million in 2024. The market is experiencing steady growth driven by the rising number of women-particularly in the aging population-affected by stress urinary incontinence (SUI). Heightened awareness around pelvic health, along with increased access to specialized urogynecology centers, has encouraged more women to pursue treatment for urinary incontinence. Contributing factors such as obesity, childbirth, and menopause continue to raise the incidence of pelvic floor disorders, leading to higher demand for surgical interventions like vaginal slings. Advancements in sling materials and the adoption of minimally invasive surgical techniques are improving procedural efficiency, shortening recovery times, and enhancing overall patient satisfaction, all of which support market expansion.Additionally, strong healthcare infrastructure combined with favorable reimbursement policies is further propelling market growth across the U.S.

Leading companies active in the Global Vaginal Slings Market include: UroCure, A.M.I., Betatech, Coloplast, UNISUR, Boston Scientific, ADLER, Promedon, CALDERA MEDICAL, Johnson & Johnson, COUSIN SURGERY, neomedic international, LOTUS, and B. Braun. To strengthen their position in the vaginal slings market, key players are focusing on a mix of innovation, accessibility, and global outreach. Many companies are enhancing product lines with lightweight, biocompatible, and patient-centric sling materials that support quicker recovery and reduce surgical complexity. Strategic collaborations with healthcare institutions and surgeons help improve procedural adoption and product feedback. Firms are also investing in clinical trials and regulatory approvals to expand their geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Product
    • 2.2.3 Incontinence type
    • 2.2.4 Type
    • 2.2.5 End Use
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Surging prevalence of urinary incontinence (UI)
      • 3.2.1.2 Increase in cases of gynecological issues
      • 3.2.1.3 Increasing advancements in surgical techniques
      • 3.2.1.4 Rising awareness of pelvic floor disorders and their treatment options
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of vaginal sling procedure
      • 3.2.2.2 Safety and efficacy concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Rest of the world
  • 3.5 Technology and innovation landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Price trends
    • 3.6.1 By region
    • 3.6.2 By product
  • 3.7 Future market trends
  • 3.8 Reimbursement scenario
    • 3.8.1 Impact of reimbursement policies on market growth
  • 3.9 Consumer behaviour analysis
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Rest of the world
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Transobturator slings
  • 5.3 Tension-free vaginal tape slings
  • 5.4 Mini-slings

Chapter 6 Market Estimates and Forecast, By Incontinence Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Stress incontinence
  • 6.3 Mixed incontinence
  • 6.4 Urge incontinence

Chapter 7 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Midurethral sling
  • 7.3 Traditional sling

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Ambulatory surgical centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 ADLER
  • 10.2 A.M.I.
  • 10.3 B. Braun
  • 10.4 Betatech
  • 10.5 Boston Scientific
  • 10.6 CALDERA MEDICAL
  • 10.7 Coloplast
  • 10.8 COUSIN SURGERY
  • 10.9 Johnson&Johnson
  • 10.10 LOTUS
  • 10.11 neomedic international
  • 10.12 Promedon
  • 10.13 UNISUR
  • 10.14 UroCure
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦